Sandoz, Momenta sign $75mm generics deal
Momenta Pharmaceuticals (engineering complex sugars) has agreed to work with Novartis's Sandoz generics division to exclusively develop four follow-on complex generic versions of already approved recombinant therapeutics.
- Generic Drugs
- Large Molecule
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.